Edition:
United States

Corcept Therapeutics Inc (CORT.OQ)

CORT.OQ on NASDAQ Stock Exchange Capital Market

10.12USD
24 Mar 2017
Change (% chg)

$0.13 (+1.30%)
Prev Close
$9.99
Open
$9.98
Day's High
$10.24
Day's Low
$9.90
Volume
167,013
Avg. Vol
217,937
52-wk High
$11.39
52-wk Low
$4.10

Latest Key Developments (Source: Significant Developments)

Corcept Therapeutics files for mixed shelf of up to $200 mln
Monday, 13 Mar 2017 05:12pm EDT 

Corcept Therapeutics Inc : Files for mixed shelf of up to $200 million - SEC filing . In addition, 349,425 shares of co's common stock offered by the selling stockholders . Co will not receive any proceeds from the sale of co's common stock by the selling stockholders Source: (http://bit.ly/2nxNmIM) Further company coverage: [CORT.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Corcept Therapeutics posts Q4 earnings per share $0.04
Monday, 6 Mar 2017 08:30am EST 

Corcept Therapeutics Inc : Corcept Therapeutics announces fourth quarter and full-year 2016 financial results; increases 2017 revenue guidance . Q4 GAAP earnings per share $0.04 . Q4 revenue $23.8 million versus I/B/E/S view $23.8 million . Q4 earnings per share view $0.04 -- Thomson Reuters I/B/E/S . Sees FY 2017 revenue $120 million to $130 million . Corcept Therapeutics Inc qtrly non GAAP earnings per share $0.06 .Fy2017 revenue view $121.4 million -- Thomson Reuters I/B/E/S.  Full Article

Corcept Therapeutics reiterates FY 2016 revenue guidance
Tuesday, 1 Mar 2016 04:05pm EST 

Corcept Therapeutics:Reiterates Fy 2016 revenue guidance of $76-81 million.FY 2015 revenue of $79 million - Thomson Reuters I/B/E/S.  Full Article

Corcept Therapeutics gives FY 2016 revenue guidance
Thursday, 28 Jan 2016 04:05pm EST 

Corcept Therapeutics:Estimates Fy 2016 revenue will be $76-81 million.  Full Article

Corcept Therapeutics reiterates FY 2015 revenue guidance
Thursday, 5 Nov 2015 04:05pm EST 

Corcept Therapeutics:Reiterates FY 2015 revenue guidance of $49 - $53 million.FY 2015 revenue of $52 million - Thomson Reuters I/B/E/S.  Full Article

Corcept Therapeutics says to begin separate phase 2 trials of CORT125134 in Q1 2016
Tuesday, 13 Oct 2015 04:00pm EDT 

Corcept Therapeutics:Says that a poster describing the Phase 1 trial results of its next-generation cortisol modulator CORT125134 will be presented at the annual meeting of the American Association of Pharmaceutical Scientists in Orlando, Florida on October 28, 2015.  Full Article

Corcept Therapeutics Inc raises low end of prior FY 2015 revenue outlook to a range in line with analysts' estimates
Wednesday, 5 Aug 2015 04:05pm EDT 

Corcept Therapeutics Inc:Revises FY 2015 net revenue guidance from $47 - $53 million to $49 - $53 million.FY 2015 revenue of $51 million - Thomson Reuters I/B/E/S.  Full Article

Corcept Therapeutics Inc reaffirms FY 2015 revenue guidance
Thursday, 7 May 2015 04:05pm EDT 

Corcept Therapeutics Inc:Estimates FY 2015 net revenue will be between $47 million and $53 million.FY 2015 revenue of $52 million - Thomson Reuters I/B/E/S.  Full Article

More From Around the Web

BRIEF-Corcept Therapeutics files for mixed shelf of up to $200 mln

* In addition, 349,425 shares of co's common stock offered by the selling stockholders